// App-Quantinova.ai

BSH2020‐OR‐035 : Post‐transplant outcomes of children with primary haemophagocytic lymphohistiocytosis given emapalumab to control disease

Researchers

Presenter

  • M. B. Jordan

Principal Investigators

  • F. Locatelli

  • C. E. Allen

  • S. Cesaro

  • C. Rizzari

  • A. Rao

  • B. Degar

  • T. Garrington

  • J. Sevilla

  • M. C. Putti

  • F. Fagioli

  • M. Ahlmann

  • J.-L. Dapena

  • M. Henry

  • A. A. Grom

  • F. De Benedetti

  • C. de Min

Medical Centers

  • Division of Immunobiology and Bone Marrow Transplantation and Immune Deficiency, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Univ. of Cincinnati, Cincinnati, OH, USA

  • Department of Onco‐Hematology, IRCCS Bambino Gesù Children's Hospital IRCCS, Sapienza, University of Rome, Italy

  • Department of Pediatrics, Texas Children's Cancer Center, Texas Children's Hospital, Houston, TX, USA

  • Department of Paediatrics,Paediatric Haematology Oncology, Azienda Ospedaliera Universitaria Integrata Verona,Verona,Italy

  • Department of Pediatrics, San Gerardo Hospital, University of Milano‐Bicocca, Monza, Italy

  • Department of Pediatric Anesthesiology, Great Ormond Street Hospital,NHS, London, United Kingdom

  • Division of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA

  • Center for Cancer and Blood Disorders, Childrens Hospital Colorado, Aurora, CO

  • Department of Pediatric Oncohematology, University Children Hospital Niño Jesús, Madrird, Spain

  • Division of Pediatric Hematology and Oncology, Department of Pediatrics, University of Padova, Padova

  • Division of Pediatric Onco‐hematology, Regina Margherita‐S. Anna Hospital, Turin, Italy

  • Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster, Muenster, Germany

  • Department of Pediatric Hematology and Oncology, University Hospital Vall d'Hebron, Barcelona, Spain

  • Center for Cancer & Blood Disorders, Phoenix Children's Hospital, Phoenix, AZ

  • Division of Nephrology, Cincinnati Childrens Hospital Medical Center, Cincinnati, OH

  • Division of Rheumatology, IRCCS Bambino Gesù Children's Hospital, Rome, Rome, Italy

  • Swedish Orphan Biovitrum (Sobi) AG, Basel, Switzerland

Locations

  • United States

  • Italy

  • United Kingdom

  • Spain

  • Germany

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Infectious Diseases (ID)

  • Genetic Disorder

  • Autoimmune (AI)

Disease

  • Hemophagocytic lymphohistiocytosis

  • Graft-versus-host disease

  • Septic shock

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Alemtuzumab

  • fludarabine tablet

  • NI0501

  • Ovastat

  • Melphalan

  • Busulfan

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT01818492

  • NCT02069899

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved